Baxter International (BAX)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$25.83+1.02%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · BAX
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $26 BAX trades at 13× p/e, below its 28× p/e peer median. Our $28 fair value sits above the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $21–$28. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $24.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $11.69 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $15.28 | — | — | Hist. CAGR | high |
| graham number | 12M | $23.46 | — | — | TTM | high |
| Mgmt guidance |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$21.00 – $28.00 (median $24.00) · 5 analysts · as of 2026-07-31
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $0.25/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $57.95 |
| 28.3 |
| 2.05 |
| Mgmt |
| high |
| Peer EV/EBITDA | 12M | $2.60 | 6.2 | 2.70 | TTM | high |
| Peer P/FCF | 12M | $32.26 | 24.6 | 1.31 | TTM | high |
| Peer P/E | 12M | $38.29 | 18.7 | 2.05 | ntm analyst | high |
| Peer P/S | 12M | $65.18 | 2.9 | 22.14 | TTM | high |
| residual income | 12M | $15.51 | — | — | TTM | high |
| Own P/E history | 12M | $24.22 | 11.8 | 2.05 | TTM | high |
| triangulated | 12M | $62.98 | 28.3 | 2.23 | Triangulated | high |
| Mgmt guidance | 3Y | $57.38 | 28.3 | 2.03 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $25.14 | 24.6 | 1.02 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $60.20 | 18.7 | 3.22 | Analyst | medium |
| Peer P/S | 3Y | $72.83 | 2.9 | 24.74 | guidance | medium |
| Own P/E history | 3Y | $38.00 | 11.8 | 3.22 | Analyst | medium |
| Mgmt guidance | 5Y | $57.00 | 28.3 | 2.02 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $21.29 | 24.6 | 0.86 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $65.74 | 18.7 | 3.51 | Analyst | high |
| Peer P/S | 5Y | $79.53 | 2.9 | 27.02 | guidance | high |
| Own P/E history | 5Y | $41.50 | 11.8 | 3.51 | Analyst | high |